JP2016536368A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536368A5
JP2016536368A5 JP2016552435A JP2016552435A JP2016536368A5 JP 2016536368 A5 JP2016536368 A5 JP 2016536368A5 JP 2016552435 A JP2016552435 A JP 2016552435A JP 2016552435 A JP2016552435 A JP 2016552435A JP 2016536368 A5 JP2016536368 A5 JP 2016536368A5
Authority
JP
Japan
Prior art keywords
factor
composition
deficiency
hemophilia
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016552435A
Other languages
English (en)
Japanese (ja)
Other versions
JP6629744B2 (ja
JP2016536368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/063676 external-priority patent/WO2015066606A2/en
Publication of JP2016536368A publication Critical patent/JP2016536368A/ja
Publication of JP2016536368A5 publication Critical patent/JP2016536368A5/ja
Application granted granted Critical
Publication of JP6629744B2 publication Critical patent/JP6629744B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016552435A 2013-11-01 2014-11-03 第Ｘａ因子の半減期を延ばす組成物および方法 Expired - Fee Related JP6629744B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361898884P 2013-11-01 2013-11-01
US61/898,884 2013-11-01
US201361918341P 2013-12-19 2013-12-19
US61/918,341 2013-12-19
PCT/US2014/063676 WO2015066606A2 (en) 2013-11-01 2014-11-03 Compositions and methods for increasing the half-life of factor xa

Publications (3)

Publication Number Publication Date
JP2016536368A JP2016536368A (ja) 2016-11-24
JP2016536368A5 true JP2016536368A5 (cg-RX-API-DMAC7.html) 2017-12-14
JP6629744B2 JP6629744B2 (ja) 2020-01-15

Family

ID=53005403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552435A Expired - Fee Related JP6629744B2 (ja) 2013-11-01 2014-11-03 第Ｘａ因子の半減期を延ばす組成物および方法

Country Status (5)

Country Link
US (1) US20160235824A1 (cg-RX-API-DMAC7.html)
EP (1) EP3063170A4 (cg-RX-API-DMAC7.html)
JP (1) JP6629744B2 (cg-RX-API-DMAC7.html)
CA (1) CA2928762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015066606A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6133256A (en) 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
GB9908838D0 (en) * 1998-09-11 1999-06-16 Univ London Fibroblast inhibitor
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP3824902A1 (en) * 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
CN102316893B (zh) * 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
GB2485590A (en) * 2010-11-22 2012-05-23 Univ Ruprecht Karis Heidelberg Method for detecting at least one direct factor Xa inhibitors
WO2013123248A1 (en) * 2012-02-16 2013-08-22 Portola Pharmaceuticals, Inc. MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法

Similar Documents

Publication Publication Date Title
Naudin et al. Factor XII contact activation
Levi et al. Coagulation and sepsis
Draxler et al. Plasmin: a modulator of immune function
Key et al. Coagulation factor concentrates: past, present, and future
Petersen et al. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor
Collen The plasminogen (fibrinolytic) system
Davalos et al. Fibrinogen as a key regulator of inflammation in disease
Okamoto et al. Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis
Yaron et al. Fibrinolytic serine proteases, therapeutic serpins and inflammation: fire dancers and firestorms
Pryzdial et al. Blood coagulation dissected
Hedner et al. First 20 years with recombinant FVIIa (NovoSeven)
Sharma et al. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension
Rengasamy et al. Bioactive peptides and proteins as alternative antiplatelet drugs
Pathak et al. Cell receptor and cofactor interactions of the contact activation system and factor XI
Chun et al. Case 1—2005: Cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease
Zhong et al. Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis
JP2016536368A5 (cg-RX-API-DMAC7.html)
Subramaniam et al. Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor
Seligsohn et al. Inherited deficiencies of coagulation factors II, V, VII, XI and XIII and the combined deficiencies of Factors V and VIII and of the Vitamin K dependent factors
US20250099540A1 (en) Methods and pharmaceutical composition for treating thrombotic disorders
US20160235824A1 (en) Compositions and Methods for Increasing the Half-Life of Factor XA
Pilli Understanding the clotting cascade, regulators, and clinical modulators of coagulation
Howard et al. Activated protein C
Levi The Coagulation System in Sepsis
ES2532978T3 (es) Especialidades farmacéuticas para el tratamiento de trastornos de coagulación de la sangre que contienen concentrado de factor XIa sin trombina